Calidi Biotherapeutics Names New CEO, Grants Significant Stock Option Package
Calidi Biotherapeutics has appointed Eric Poma as its new CEO and granted him a substantial stock option package, signaling potential strategic shifts in the clinical-stage biotechnology company's leadership and future direction.
Calidi Biotherapeutics, a clinical-stage biotechnology company focused on targeted antitumor virotherapies, has appointed Eric Poma, Ph.D., as its new Chief Executive Officer. As part of his onboarding, the company's board approved a significant inducement stock option grant aligned with standard corporate governance practices.
The stock option grant allows Poma to purchase 726,412 shares at an exercise price of $0.469 per share, which corresponds to the company's closing stock price on April 22, 2025. The options will vest over a four-year period, with 25% becoming available on April 22, 2026, and the remaining shares vesting in equal monthly installments through April 22, 2029.
This compensation structure is designed to align the new CEO's financial interests with the company's long-term performance and shareholder value. For Calidi Biotherapeutics, the appointment signals potential strategic momentum in its mission to develop innovative stem cell-based platforms for cancer treatment.
The company specializes in proprietary technology that leverages allogeneic stem cells to deliver oncolytic viruses, with a focus on addressing challenging oncological indications including high-grade gliomas and solid tumors. Their preclinical platforms aim to enhance the efficacy and safety of cancer treatments by protecting, amplifying, and potentiating oncolytic viruses.
Poma's appointment and substantial stock option grant suggest the company is positioning itself for potential growth and continued innovation in the biotechnology sector, particularly in advanced cancer therapies.